Industry Comments Show Support For MCIT Proposed Rule – With Reservations
AdvaMed, MDMA strongly back the Medicare coverage proposal, but want agency to back off codifying a definition for ‘reasonable and necessary’
Industry groups were cool to parts of the CMS’s proposed Medicare Coverage of Innovative Technology (MCIT) rule dealing with commercial insurance coverage, as well as definitions used in the proposal.
You may also be interested in...
The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.
Both insurance group AHIP and the MedPAC group of Medicare advisors are insisting on CMS reimbursement for medical devices only supported by clinical trials. Industry attorneys weigh in.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.